What Is Pentosan Polysulfate? Benefits, Research & Safety

PPS was first synthesised in the 1950s as part of research into heparin-like anticoagulant compounds. Its chemical structure resembles heparin and other naturally occurring glycosaminoglycans, giving it a range of biological activities. Initial therapeutic use focused on anticoagulant and fibrinolytic properties. The discovery that PPS could protect the bladder's GAG layer led to its development for interstitial cystitis, and Baker Norton Pharmaceuticals obtained FDA approval for Elmiron in 1996. In veterinary medicine, PPS (as Cartrophen) became one of the most widely used disease-modifying osteoarthritis drugs (DMOADs) for dogs, with extensive evidence supporting its chondroprotective effects. Research into human osteoarthritis applications accelerated in the 2000s and 2010s, with clinical trials in Australia showing significant benefits with subcutaneous PPS injections for knee osteoarthritis. In 2018-2019, reports emerged linking long-term oral PPS (Elmiron) use to a unique pigmentary maculopathy. This led to FDA label updates and increased ophthalmological monitoring requirements, though the risk appears dose- and duration-dependent.